Brind.
  1. Solvonis Therapeutics plc announced its AGM results and updated its clinical portfolio progress on the London Stock Exchange.

Solvonis Therapeutics plc holds investor webinar featuring David Nutt

1 report, 1 independent Updated Oct 6
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Solvonis Therapeutics plc is hosting an investor webinar to discuss its strategy for translating advances in neuropsychopharmacology into potential treatments for addiction and psychiatric disorders. The webinar will be chaired by Barry Gibb, and David Nutt serves as Chief Scientific Officer for the company. The event is scheduled for October 15, 2026.

From investegate.co.uk

Why it matters

Some supportBrind's analysis of the reports

Solvonis Therapeutics plc is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for central nervous system disorders. The discussion is set against a backdrop of growing interest in mental health treatment, including coverage of psychedelic therapies potentially entering National Health Service care.

Solvonis Therapeutics plc recently announced its AGM results and updated its clinical portfolio progress on the London Stock Exchange.

From investegate.co.uk

Who's involved

  • Barry GibbChaired the investor webinar for Solvonis Therapeutics plc.
  • David NuttServes as Chief Scientific Officer for Solvonis Therapeutics plc.

Keep exploring

Part of

Solvonis Therapeutics plc announced its AGM results and updated its clinical portfolio progress on the London Stock Exchange. All 2 developments

The entities involved

  • Barry Gibb

    British musician

    Nothing else this week.

  • David Nutt

    British psychiatrist, neuropsychopharmacologist

    Nothing else this week.

Coverage

Newest first; wire copies grouped